MeadeT.W., MellowsS., BrozovicM., MillerG.J., ChakrabartiR.R., NorthW.R.S.Haemostatic function and ischaemic heart disease: principal results of the Nortwick Park heart study.Lancet1986; II: 533–7.
2.
HeinrichJ., BalleisenL., SchulteH.G.A., van de LooJ.Fibrinogen and factor VII in prediction of coronary risk: results from the PROCAM study in healthy men.Arterioscler Thromb1994; 71: 719–22.
BartensW., NauckM., SchollmeyerP., WannerC.Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients.Perit Dial Int1996; 16: 27–33.
5.
IrishA.Cardiovascular disease, fibrinogen and the acute phase response: association with lipids and blood pressure in patients with chronic renal disease.Atherosclerosis1998; 137: 133–9.
6.
MaraisA.D., FirthJ.C., BatemanM.E., ByrnesP., MartensC., MountneyJ.Atorvastatin: an effective agent in familial hypercholesterolaemia.Arterioscler Thromb Vasc Biol1997; 17: 1527–32.
7.
WierzbickiA.S., LumbP.J., SemraY.K., CrookM.A.Effect of atorvastatin on plasma fibrinogen.Lancet1998; 351: 569–70.
8.
DavidsonM., McKenneyJ., SteinE., SchrottH., Bakker– ArkemaR., FayyadR., for the Atorvastatin Study Group I. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercho-lesterolemia.Am J Cardiol1997; 79: 1475–81.
